Developing A Second Melanoma What are the Chances of Developing a Second Melanoma? If you have had melanoma in the past, you are at…
Risk Assessment …melanoma in the past? People who have already been diagnosed with melanoma have an increased risk of developing another melanoma…
Early Detection Can Melanoma Be Found Early? Melanoma is one of the most common cancers diagnosed in the United States and the…
Newly Diagnosed Recently Diagnosed With Melanoma? If you’ve been diagnosed with melanoma, your mind is probably overloaded with questions and worries. Worries…
Share Your Story Share Your Melanoma Story Melanoma doesn’t affect only the person with the illness. It affects family members and friends as…
Melanoma Staging …specifics on the TNM categories and melanoma staging. https://youtu.be/e1JLPVN_zkE Melanoma Staging The five stages of melanoma are described here: Stage…
AIM at Melanoma – Reshaping the Future Together …battle this disease.\n\n 1-833-236-3635\n\n Live Chat\n\n Email\n\n A WORLD FREE OF MELANOMA\n\n Melanoma is a potentially fatal disease that is…
Women in Melanoma Women In Melanoma: AIM’s Latest Success Story AIM at Melanoma is always looking for innovative and effective ways to support…
Advances in Melanoma Treatment | Jan. 13, 2025 …the future of patient care. https://youtube.com/live/cRuVVKBB9HI Key Topics of Discussion: Current Research in Melanoma Treatment: Explore the latest studies…
Moles …because when melanoma is found and treated early, the chances for long-term survival are excellent. As melanoma progresses, it becomes…
Jun. 09, 2026 The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public
Jun. 05, 2026 Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026 Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026 Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors